Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | STK17B | O94768 | 1/20 | 0.31 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458765 | 0.92 | HPRT1 (0.34) | CKS1BSKP1SKP2CCNE2CCNE1 | |
| SCHEMBL15235916 | 0.91 | CKS1B (0.35) | CKS1BSKP1SKP2CCNE2CCNE1 | |
| SCHEMBL459081 | 0.86 | MAPT (0.37) | CKS1BSKP1SKP2CCNE2CCNE1 | |
| SCHEMBL13037053 | 0.86 | CKS1B (0.35) | CKS1BSKP1SKP2CCNE2CCNE1 | |
| SCHEMBL431141 | 0.84 | CCNE2 (0.36) | CKS1BSKP1SKP2CCNE2CCNE1 | |
| SCHEMBL432421 | 0.84 | CKS1B (0.36) | CKS1BSKP1SKP2CCNE2CCNE1 | |
| SCHEMBL10078207 | 0.83 | CKS1B (0.34) | CKS1BSKP1SKP2CCNE2CCNE1 | |
| SCHEMBL430139 | 0.81 | CKS1B (0.36) | CKS1BSKP1SKP2CCNE2CCNE1 | |
| SCHEMBL460716 | 0.80 | MAPT (0.36) | CKS1BSKP1SKP2CCNE2CCNE1 | |
| SCHEMBL10078205 | 0.79 | HPRT1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2013-09-05 | — | — | US | disclosed |
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2013-09-05 | — | — | US | disclosed |
| EP-2596102-A2 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GeneArrest Ltd (IL) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012011114-A2 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012011114-A2 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | POLM, POLRMT, DDB1 | CKS1B 1491/4885SKP1 4052/4885SKP2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.